SEOUL/SHANGHAI (Reuters) -Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already broken ground on U.S. manufacturing plants.

In South Korea, Samsung Biologics fell 1.6%, while SK Biopharmaceuticals slid 2.6%.

But Celltrion, which said on Tuesday it had paid $330 million to acquire ImClone Systems LLC from Eli Lilly in the United States, rose 1.3% after recouping losses.

In Japan, Sumitomo Pharma tumbled 4.3%, Otsuka Holdings dropped 3.5%, and Daiichi Sankyo lost 1.6%, although Takeda added 0.2% and Shionogi gained 1.3%.

Hong Kong’s Hang Seng Biotech Index was down about 2.58%.

Markets had already been braced for further tariffs and investigations

See Full Page